2023 World Conference on Lung Cancer (Posters)-P1.22. Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study

P1.22. Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study - PDF(Slides)

Back to course

Pdf Summary

A poster presented at the IASLC World Conference on Lung Cancer discussed the use of plasma ctDNA genotyping as a pre-tissue diagnosis approach in patients with suspected advanced non-small cell lung cancer (NSCLC). The study aimed to evaluate the benefits of this approach in terms of accelerating time to treatment and detecting more actionable alterations.<br /><br />The study, called ACCELERATE, enrolled 150 patients between July 2021 and November 2022. These patients underwent plasma ctDNA testing using a next-generation sequencing (NGS) assay called InvisionFirst-Lung before a lung cancer diagnosis was made. The primary endpoint of the study was the time from referral to treatment initiation in patients with advanced nonsquamous NSCLC using ctDNA testing.<br /><br />The results showed that using plasma ctDNA genotyping before tissue diagnosis shortened the time to treatment initiation and identified more actionable alterations. Of the 74 patients who had sufficient tissue for NGS, 72 started systemic therapy. The study also identified 53 actionable alterations, with 35 found in both plasma and tissue, 7 found in tissue only, and 11 found in plasma only.<br /><br />The researchers concluded that a plasma-first approach can expedite access to precision medicine and potentially improve patient outcomes. This approach could serve as a complement to tumor tissue profiling in advanced NSCLC. They proposed an algorithm where plasma NGS results are used to prioritize tissue sampling, pathologic diagnosis, and subtyping before treatment initiation.<br /><br />Overall, this study highlights the potential benefits of using plasma ctDNA genotyping as a pre-tissue diagnosis approach in patients with suspected advanced NSCLC. It can accelerate access to precision medicine, shorten the time to treatment initiation, and provide more information about actionable alterations, ultimately leading to improved patient outcomes.

Asset Subtitle

Natasha Leighl

Meta Tag

Speaker Natasha Leighl

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

plasma ctDNA genotyping

pre-tissue diagnosis

advanced non-small cell lung cancer

NSCLC

ACCELERATE study

plasma ctDNA testing

next-generation sequencing

time to treatment initiation

actionable alterations

precision medicine